Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3721 in moderate to severe COPD
NCT06527144Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQC3721 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Change of the maximum value of Forced Expiratory Volume in the first second (FEV1) at 4 weeks. Started Sep 2024; status: completed.
02
Drugs
TQC3721
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06527144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527144.